Participants were referred for a comprehensive periodontal examination that included plaque index, bleeding on probing, probing depth, gingival recession, clinical attachment level, and assessment of ...
Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google When you have secondary progressive multiple sclerosis (SPMS), ...
uniQure is targeting a BLA submission in the first quarter of 2026. Topline data were announced from a pivotal phase 1/2 study evaluating AMT-130 in patients with Huntington disease (HD). AMT-130 is a ...
The last time I wrote an article on uniQure N.V. (QURE), it was in a Seeking Alpha article entitled "uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting." With respect to that article, ...
~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external ...
uniQure reported positive topline data from the pivotal Phase I/II study of AMT-130 for the treatment of Huntington’s disease. The study met its prespecified primary endpoint, with high-dose AMT-130 ...
Improved HDL-C metrics were associated with better scores on cognitive performance tests at midlife among women. Improved serum high-density lipoprotein (HDL) metrics during midlife are associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results